<DOC>
	<DOCNO>NCT02254863</DOCNO>
	<brief_summary>The primary objective study determine safety feasibility intrathecal administration DUOC-01 adjunctive therapy patient inborn error metabolism evidence early demyelinating disease central nervous system ( CNS ) undergo standard treatment unrelated umbilical cord blood transplantation ( UCBT ) . The secondary objective study describe efficacy UCBT intrathecal administration DUOC-01 patient .</brief_summary>
	<brief_title>UCB Transplant Inherited Metabolic Diseases With Administration Intrathecal UCB Derived Oligodendrocyte-Like Cells</brief_title>
	<detailed_description>The inherited metabolic disorder ( IMD ) heterogeneous group genetic disease , involve single gene mutation result enzyme defect . In majority case , enzyme defect lead accumulation substrate toxic and/or interfere normal cellular function . Often time , patient may appear normal birth infancy begin exhibit disease manifestation , frequently include progressive neurological deterioration due absent abnormal brain myelination . The ultimate result death later infancy childhood . Currently , effective therapy halt neurologic progression disease allogeneic hematopoietic stem cell transplantation ( HSCT ) , serve source permanent cellular ERT.3 However , one barrier success therapy delay engraftment donor cell CNS administer intravenous route , associate ongoing disease progression 2-4 month stabilization . The engraftment donor cell patient IMD provide constant source enzyme replacement , thereby slow halt progression disease . This study evaluate safety potential new treatment patient certain IMDs know benefit HSCT use allogeneic UCB donor cell . The new intervention , intrathecal administration UCB-derived oligodendrocyte-like cell ( DUOC-01 ) serve adjunctive therapy standard UCB transplant . The goal therapy accelerate delivery donor cell CNS thereby bridge gap systemic transplant engraftment cell CNS prevent disease progression . The DUOC-01 cell cell use HSCT derive UCB donor unit .</detailed_description>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Tay-Sachs Disease</mesh_term>
	<mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<mesh_term>Sandhoff Disease</mesh_term>
	<mesh_term>Leukodystrophy , Globoid Cell</mesh_term>
	<mesh_term>Pelizaeus-Merzbacher Disease</mesh_term>
	<mesh_term>Brain Diseases , Metabolic</mesh_term>
	<mesh_term>Brain Diseases , Metabolic , Inborn</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<criteria>1 . Patients must age ≥1 week &lt; 21 year . 2 . Patients must one follow inherit metabolic disease detect enzyme mutation analysis , confirm repeat test separately obtain sample : Adrenoleukodystrophy ( ALD ) Batten Disease Hunter Syndrome ( MPS II ) Krabbe disease ( Globoid Leukodystrophy ) Metachromatic Leukodystrophy ( MLD ) Niemann Pick disease type A B PelizaeusMerzbacher disease ( PMD ) Sandhoff disease Tay Sachs disease . 3 . Patients must neurologic evidence disease , either clinically via neuroimaging neurophysiological testing . Examples evidence neurologic involvement include , limited following : Abnormal EEG , Brainstem Auditory Evoked Response ( BAER ) , and/or Visual Evoked Potentials ( VEP ) . Abnormal brain MRI , ie . increase Loes score ( measure white matter damage , demyelination , brain atrophy ) and/or abnormal corticospinal tract assess MRI diffusion tensor imaging ( DTI ) . Three early clinical marker : problem sleep , increased activity , behavior difficulty , seizurelike activity , chew behavior , inappropriate bladder training , inappropriate bowel training . 4 . Patients must adequate organ function measure : Renal : Serum creatinine &lt; 2.0 mg/dl Hepatic : Hepatic transaminase ( ALT/AST ) &lt; 5 x normal , bilirubin &lt; 2.0 mg/dl ( except patient Gilbert 's disease newborns physiological breast milk associate jaundice ) . Cardiac : Normal cardiac function echocardiogram radionuclide scan ( shorten fraction ejection fraction 80 % normal value age ) . Patients acquire congenital cardiomyopathy may receive melphalan substitute cyclophosphamide . Pulmonary : Pulmonary function test demonstrate FVC , FEV1 , DLCO ≥ 60 % predict patient complete test . If patient perform PFT 's , O2 sit must &gt; 90 % room air . 5 . Patients must suitable fully match , noncarrier sibling related bone marrow donor . 6 . Patients must available , suitably match , bank UCB unit twocompartment configuration ( see graft selection criterion section 5.2 ) . 7 . Patients must performance status follow : Lansky ≥ 40 % , Karnofsky ≥ 40 % . 8 . Patients must life expectancy ≥ 6 month . 1 . Prior organ , tissue , stem cell transplant within 3 year study entry . 2 . Prior participation gene regenerative cell therapy study . 3 . Inability MRI scan lumbar puncture . 4 . Intractable seizure . 5 . Chronic aspiration . 6 . Bleeding disorder . 7 . Evidence HIV infection HIV positive serology . 8 . Uncontrolled bacterial , viral , fungal infection time preUCBT cytoreduction . 9 . Inability obtain patient 's , parent 's legal guardian 's consent . 10 . Requirement ventilatory support . 11 . Pregnant breastfeeding . 12 . Active concurrent malignancy , receive concurrent radiotherapy , immunosuppressive medication , cytotoxic chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Adrenoleukodystrophy</keyword>
	<keyword>Batten Disease</keyword>
	<keyword>Hunter Syndrome</keyword>
	<keyword>Krabbe</keyword>
	<keyword>Metachromatic Leukodystrophy</keyword>
	<keyword>ALD</keyword>
	<keyword>MLD</keyword>
	<keyword>PMD</keyword>
</DOC>